新型BNP1-32免疫测定法不与非活性proBNP交叉反应
研究开发了基于Luminex的BNP1-32特异性免疫分析法,在42例心衰患者和22例健康对照中与三种现有BNP assay比较。该法对proBNP交叉反应≤0.1%,检测限0.35 ng/L,批内和批间CV<15%,且NYHA IV级心衰患者浓度倍数增加显著高于Abbott BNP和BNP RIA。
要点
- 新BNP1-32免疫法对proBNP交叉反应≤0.1%,检测限0.35 ng/L,CV<15%。
- NYHA IV级心衰患者中,BNP1-32法浓度倍数增加显著高于Abbott BNP及BNP RIA。
- 新法可特异性测量有生物活性的BNP1-32,避免proBNP干扰,尚需更大队列验证。
核心结论
- 成功开发首个不受proBNP干扰的血浆BNP1-32免疫测定法。
研究设计与样本
- 研究开发基于Luminex的BNP1-32免疫分析法,并与三种现有BNP assay在42例心衰患者和22例健康对照血浆中比较。
主要发现
- BNP1-32 assay与BNP2-32交叉反应57%,与BNP3-32、其他BNP代谢物及proBNP交叉反应≤0.1%。
- 检测限为0.35 ng/L,批内和批间CV均<15%。
- 健康对照和心衰患者中BNP1-32中位浓度分别为0.3 ng/L和40.7 ng/L。
- NYHA IV级心衰患者中,BNP1-32法的浓度倍数增加显著高于Abbott BNP(P=0.026)和BNP RIA(P<0.0001),但与total-BNP assay无显著差异。
临床怎么用
- 该法可特异性测量有生物活性的BNP1-32,避免proBNP干扰,但尚需更大队列比较诊断或预后性能。
局限性
- 需更大患者队列比较该法与现有低特异性assay在心力衰竭诊断或预后中的性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma B-type natriuretic peptide (BNP) concentration reflects cardiac dysfunction and assists in determining the diagnosis and prognosis of heart failure (HF). Current BNP assays overestimate circulating bioactive BNP1-32 concentrations as they also detect less active BNP metabolites and proBNP. A specific BNP1-32 assay with negligible cross-reactivity to proBNP and/or BNP metabolites may be advantageous. METHODS: We developed a Luminex-based specific BNP1-32 immunoassay and compared results obtained from 3 other BNP assays (a Luminex-based total-BNP assay, our BNP RIA, and the commercially available Abbott Architect BNP assay) in plasma from 42 patients with HF and 22 healthy controls. RESULTS: The BNP1-32 assay showed 57% cross-reactivity with BNP2-32, but ≤0.1% cross-reactivity to BNP3-32, other BNP metabolites, and proBNP; its detection limit was 0.35 ng/L; and intra- and interassay CVs were <15%. BNP immunoreactivity increased with HF severity (median concentrations being 0.3, 0.8, 26.2, and 17.3 ng/L in healthy controls and 40.7, 139, 465, and 1778 ng/L in HF patients for the BNP1-32, total-BNP, BNP RIA, and Abbott BNP assays respectively). The fold increase between HF cases with the New York Heart Association (NYHA) class IV was significantly greater with the BNP1-32 assay than the Abbott BNP (P = 0.026) and the BNP RIA (P < 0.0001) but not the total-BNP assay. CONCLUSIONS: We have developed the first assay that measures BNP1-32 in plasma without interference by proBNP. Analysis of larger patient cohorts is now required to compare the performance of this assay with current less specific assays for the diagnosis or prognosis of HF.
引用
- Lewis LK, Raudsepp SD, Yandle TG, et al. Development of a BNP1-32 Immunoassay That Does Not Cross-React with proBNP. Clin Chem. 2017. PMID: 28428353. doi:10.1373/clinchem.2016.269712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。